CAR T-Cell Therapy Market
CAR T-Cell Therapy Market - Global Industry Assessment & Forecast
#
Pages:
180
Base Year:
2022
Nov - 2023
Format:
Report Code:
VMR-2336
Segments Covered
By
Drug Type Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Other Drug Types
-
By
Indication Lymphoma, Acute Lymphocytic Leukemia, Other Indications
-
By
End User Hospitals, Cancer Treatment Centers
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 2 Billion |
 Revenue 2030:
|
USD 5.9 Billion |
 Revenue CAGR
(2023 - 2030): |
14.6% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
CAR T-Cell Therapy Market Segment Analysis
- CAR T-Cell Therapy Drug Type Outlook (Revenue, USD Million, 2018 - 2030)
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- CAR T-Cell Therapy Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- CAR T-Cell Therapy End User Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Cancer Treatment Centers
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
-
North America CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
-
North America CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- U.S.
- U.S. CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- U.S. CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- U.S. CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- U.S. CAR T-Cell Therapy Market, by Drug Type
- Canada
- Canada CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Canada CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Canada CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Canada CAR T-Cell Therapy Market, by Drug Type
-
Mexico
- Mexico CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Mexico CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Mexico CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Mexico CAR T-Cell Therapy Market, by Drug Type
-
North America CAR T-Cell Therapy Market, by Drug Type
- Europe
-
Europe CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
-
Europe CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
-
Europe CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- U. K.
- U.K. CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- U.K. CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- U.K. CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- U.K. CAR T-Cell Therapy Market, by Drug Type
- France
- France CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- France CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- France CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- France CAR T-Cell Therapy Market, by Drug Type
-
Germany
- Germany CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Germany CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Germany CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Germany CAR T-Cell Therapy Market, by Drug Type
-
Italy
- Italy CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Italy CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Italy CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Italy CAR T-Cell Therapy Market, by Drug Type
-
Spain
- Spain CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Spain CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Spain CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Spain CAR T-Cell Therapy Market, by Drug Type
-
Rest of Europe
- Rest of Europe CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Rest of Europe CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Rest of Europe CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Rest of Europe CAR T-Cell Therapy Market, by Drug Type
-
Europe CAR T-Cell Therapy Market, by Drug Type
- Asia Pacific
-
Asia Pacific CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
-
Asia Pacific CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
-
Asia Pacific CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- China
- China CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- China CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- China CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- China CAR T-Cell Therapy Market, by Drug Type
- Japan
- Japan CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Japan CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Japan CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Japan CAR T-Cell Therapy Market, by Drug Type
-
Germany
- Germany CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Germany CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Germany CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Germany CAR T-Cell Therapy Market, by Drug Type
-
India
- India CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- India CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- India CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- India CAR T-Cell Therapy Market, by Drug Type
-
South Korea
- South Korea CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- South Korea CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- South Korea CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- South Korea CAR T-Cell Therapy Market, by Drug Type
-
South East Asia
- South East Asia CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- South East Asia CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- South East Asia CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- South East Asia CAR T-Cell Therapy Market, by Drug Type
-
Rest of Asia Pacific
- Rest of Asia Pacific CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Rest of Asia Pacific CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Rest of Asia Pacific CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Rest of Asia Pacific CAR T-Cell Therapy Market, by Drug Type
-
Asia Pacific CAR T-Cell Therapy Market, by Drug Type
- Latin America
-
Latin America CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
-
Latin America CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
-
Latin America CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Brazil
- Brazil CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Brazil CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Brazil CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Brazil CAR T-Cell Therapy Market, by Drug Type
- Argentina
- Argentina CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Argentina CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Argentina CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Argentina CAR T-Cell Therapy Market, by Drug Type
-
Rest of Latin America
- Rest of Latin America CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Rest of Latin America CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Rest of Latin America CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Rest of Latin America CAR T-Cell Therapy Market, by Drug Type
-
Latin America CAR T-Cell Therapy Market, by Drug Type
- Middle East & Africa
-
Middle East & Africa CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
-
Middle East & Africa CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
-
Middle East & Africa CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- GCC Countries
- GCC Countries CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- GCC Countries CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- GCC Countries CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- GCC Countries CAR T-Cell Therapy Market, by Drug Type
- South Africa
- South Africa CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- South Africa CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- South Africa CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- South Africa CAR T-Cell Therapy Market, by Drug Type
-
Rest of Middle East & Africa
- Rest of Middle East & Africa CAR T-Cell Therapy Market, by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Other Drug Types
- Rest of Middle East & Africa CAR T-Cell Therapy Market, by Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Other Indications
- Rest of Middle East & Africa CAR T-Cell Therapy Market, by End User
- Hospitals
- Cancer Treatment Centers
- Rest of Middle East & Africa CAR T-Cell Therapy Market, by Drug Type
-
Middle East & Africa CAR T-Cell Therapy Market, by Drug Type
- North America
Vantage Market
Research | 22-Nov-2023
FAQ
Frequently Asked Question
What is the global demand for CAR T-Cell Therapy in terms of revenue?
-
The global CAR T-Cell Therapy valued at USD 2 Billion in 2022 and is expected to reach USD 5.9 Billion in 2030 growing at a CAGR of 14.6%.
Which are the prominent players in the market?
-
The prominent players in the market are Celgene Corporation (U.S.), Cartesian Therapeutics Inc. (U.S.), Miltenyi Biotech (Germany), Autolus Therapeutics (UK), Caribou Biosciences Inc. (U.S.), Gilead Sciences Inc. (U.S.), Merck & Co. Inc. (U.S.), Intellia Therapeutics (U.S.), Juno Therapeutics Inc. (U.S.), Bristol-Myers Squibb (U.S.), Novartis AG (Switzerland), Bluebird Bio Inc. (U.S.), Sorrento Therapeutics Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis (France), Celyad Oncology (Belgium).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 14.6% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the CAR T-Cell Therapy include
- Surge in prevalence of cancer
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the CAR T-Cell Therapy in 2022.
